Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
Recap by typeshit. Video by @gma on TikTok.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
18:51
A doctor walks through four of the most talked about weight loss drugs in one overview, covering the big names people ask about most.
Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
Medscape asks if Eli Lilly's experimental triple-acting drug could help patients who stall on current GLP-1 treatments. Few details are given beyond the headline.
Loading…